Additionally, in lung adenocarcinoma, loss of DSG2 (via gene silencing) leads to the nuclear translocation of EGFR, as well as suppression of EGFR signaling via the Src-Rac1-PAK1 pathway (16). This evidence concerns the gene EGFR and lung adenocarcinoma.